|
MRPL19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.78849999999953E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.55839999999419E-05 |
| Normal-vs-Stage2 |
2.392200E-01 |
| Normal-vs-Stage3 |
9.52679999999262E-07 |
| Normal-vs-Stage4 |
2.59650000000722E-06 |
| Stage1-vs-Stage2 |
6.676300E-02 |
| Stage1-vs-Stage3 |
6.015600E-02 |
| Stage1-vs-Stage4 |
4.838200E-02 |
| Stage2-vs-Stage3 |
3.158800E-03 |
| Stage2-vs-Stage4 |
4.381200E-03 |
| Stage3-vs-Stage4 |
6.323800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.34399999982693E-07 |
| Normal-vs-AfricanAmerican |
4.392200E-02 |
| Normal-vs-Asian |
3.558000E-03 |
| Caucasian-vs-AfricanAmerican |
1.848990E-01 |
| Caucasian-vs-Asian |
3.430800E-01 |
| AfricanAmerican-vs-Asian |
5.821200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.72550000005134E-06 |
| Normal-vs-Female |
7.53650000000494E-05 |
| Male-vs-Female |
1.296780E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.40879999999977E-05 |
| Normal-vs-Age(41-60Yrs) |
2.37709999999502E-05 |
| Normal-vs-Age(61-80Yrs) |
4.447900E-04 |
| Normal-vs-Age(81-100Yrs) |
9.992200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.646400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.278600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.715800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.912000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.467200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.410600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.131200E-01 |
| Classical-VS-Follicular |
3.483700E-02 |
| Classical-VS-Other |
9.653200E-01 |
| Classical-VS-Normal |
2.30590000005471E-06 |
| Tall-VS-Follicular |
6.572300E-02 |
| Tall-VS-Other |
9.400400E-01 |
| Tall-VS-Normal |
6.200100E-04 |
| Follicular-VS-Other |
4.862000E-01 |
| Follicular-VS-Normal |
6.404400E-02 |
| Other-VS-Normal |
8.654100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.843200E-04 |
| Normal-vs-N1 |
2.35759999966945E-07 |
| N0-vs-N1 |
1.027570E-02 |
|
|
